Forge and Basilea aim to develop new antibiotics with potent and selective inhibition. Credit: Phoenix Locklear from Pixabay.

Forge Therapeutics has partnered with Basilea Pharmaceutica for the discovery, development and commercialisation of new antibiotics.

The alliance will use Forge’s metalloenzyme chemistry platform Blacksmith to develop potent inhibitors targeting two unexploited targets. These areas play key roles in multiple biological functions in bacteria.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“Linking our novel chemistry with Basilea’s deep drug development and commercial expertise will be a powerful combination in addressing the global threat of antibacterial resistance.”

The Blacksmith platform comprises information on metalloenzymes, bioinorganic and medicinal chemistry, and metal-binding fragment pharmacophores (MBP). These MBPs are said to offer selective and unique starting points for new inhibitors.

Forge Therapeutics CEO Zachary Zimmerman said: “We are excited to partner with Basilea, a global leader in anti-infective research and development, to pursue novel metalloenzyme targets that have significant promise in this challenging therapeutic area.

“We believe that linking our novel chemistry with Basilea’s deep drug development and commercial expertise will be a powerful combination in addressing the global threat of antibacterial resistance.”

Basilea Pharmaceutica chief scientific officer Laurenz Kellenberger added: “Forge’s platform complements our focused approach to discover antibiotics with new mechanisms of action that have the potential to make a difference to patients’ lives.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the agreement, Basilea will gain access to the Blacksmith platform for two targets.

Forge will also be eligible for up to $167m in development and sales milestones for each target, along with tiered royalties upon commercialisation of each antibiotic resulting from the deal.